Select a Region

North America

EVERSANA COMPLETE Commercialization®

Drive Value, Minimize Risk and Increase Speed to Market

Next Generation Commercialization

Companies spend >$200MM over three years leading up to launch, and 66% of drugs still don’t meet launch expectations. This looming risk, echoed by general industry pressures, leaves developers and investors alike looking for more advanced commercialization options that effectively maximize their pipelines.

EVERSANA COMPLETE Commercialization® , an award-winning model that is disrupting the pharma industry, offers an alternative to selling, out-licensing or launching internally.

Whether you are an emerging pharma or an established brand, this innovative model can help you achieve flexible, agile product launches that meet client and patient needs.

For small and emerging pharma, the EVERSANA COMPLETE model:

Affords investors full access to a complete end-to-end commercialization model.
Delivers more value than traditional licensing or launching on your own.
Activates a complete, ready-to-deploy, high-performance commercialization and distribution engine.
Accelerates your product from early development to marketing, effectively impacting patient outcomes and beyond.

For established brands, the EVERSANA COMPLETE model:

Eliminates capability and capacity restraints to increase the throughput of in-licensed assets.
Serves as a catalyst for biopharma companies to address the management of their established brand portfolios.

Case Studies: Real-World Impact

Leveraging our data and analytics platform, our team works together to produce the best outcomes for our partners and their patients.

AGILITY
Our team is trained to proactively monitor market conditions, the commercial readiness of the program and course-correct in an agile manner.
View Case Study
SPEED
Our integrated systems and culture allow us to mobilize the execution team quickly and communicate efficiently to create a positive customer experience.
View Case Study
Risk Management
Our proven, ready-to-deploy commercialization model minimizes operational and financial risks for our partners.
View Case Study

See how pharma companies are using this new model effectively by downloading the article Reinventing Launch: The Gold Standard of Drug Commercialization by Greg Skalicky, Chief Revenue Officer.

Download

A Deeper Dive into Our Model

Imagine not having to risk building an expensive infrastructure – because we have built a foundation you can customize for your product needs. Activate a complete, ready-to-deploy, high-performance commercialization and distribution engine today!

True Financial Benefit

A recent study examined 10 real-world pharma launches and compared them to companies that embraced this new, innovative, scalable commercialization model. The study concluded that those who launched in the traditional model overspent by 23%, without any upside on launch success. Download the white paper to see an in-depth analysis of all launches and costs.

Download

Predictable Commercial Success

Complete, full-scale, customizable infrastructure amplified by top industry launch leaders

Engineered to:

optimize the launch of precommercial assets
capture full revenue potential through maturity

Revolutionary, nontraditional financial deal structures provide flexibility of terms and options

Built to:

provide an alternative to traditional and more common strategies, such as selling it, out-licensing or going at it alone
reduce up-front cash investments necessary to launch
maximize revenue potential and minimize financial risk

Valuable assets demand integrated, predictive and actionable data to maximize growth potential

Empowered to:

maximize the ROI of data and analytic investments
enhance decision-making
create a seamless patient journey and positively impact outcomes

When A Curveball Threatens Your Product’s Launch

In this 3-minute video, Mike DeLaroche shares a new commercializing model that mitigates risk and combats curveballs that manufacturers cannot predict when launching products.

Recent EVERSANA COMPLETE Partnerships

Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection for the Treatment of T-cell Leukemia Across the United States

Shorla Oncology, a U.S.-Ireland pharmaceutical company, and EVERSANA^®, a leading provider of commercialization services to the life science industry, today announced the commercial launch of the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Read more here.

EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis

EVERSANA^®, a leading provider of commercialization services to the life science industry, today announced a partnership with ChemoMouthpiece, LLC to support the launch and commercialization of its medical device, the Chemo Mouthpiece™, to assist oncology patients across the United States. Read more here.

Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)

Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company’s first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). While maintaining financial and strategic control, Xspray Pharma will grant EVERSANA exclusive commercialization access to support its Dasynoc launch, aimed at the second half of 2023. Dasynoc, pending FDA-approval and legal conditions, will be a new and differentiated treatment option for CML and ALL patients, entering the $3.5 billion commercial market for Tyrosine Kinase Inhibitors in the United States – a market that has grown by nearly 5% in the last year alone. Read more here.

U.K.-based Nemaura Taps EVERSANA to Support Large-Scale Launch of Nemaura’s Diabetes Management Program in the U.S.

Nemaura Medical, Inc.(NASDAQ: NMRD) a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it has entered into a preliminary agreement with EVERSANA® to support all global sales and marketing of Nemaura’s Diabetes Management Solution, BEATdiabetes. Nemaura and EVERSANA will work together to develop the optimal launch strategy for large-scale adoption of the diabetes management program, including franchising and direct sales to self-insured corporate clients and healthcare insurers. Read more here.

Prosoma Digital Therapeutics and EVERSANA Announce Commercialisation Partnership for New Therapeutic Supporting Mental Health and Behavioural Needs of Cancer Patients

Prosoma Digital Therapeutics, innovators in reinventing healthcare for oncology patients, has partnered with EVERSANA® to support the expected launch and commercialisation for Prosoma’s digital therapy to support the mental health of cancer patients. Read more here.

OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuroscience Disorders

OWP Pharmaceuticals, Inc. is a privately held, neuroscience specialty pharmaceutical company announced a partnership with EVERSANA to support the launch and commercialize its portfolio of oral liquid formulations aimed to treat neuroscience disorders. Read the full announcement here.

Australian AI Company Artrya Announces Major UK Commercialisation Partnership With EVERSANA

AI medical technology company Artrya Limited announced its partnership with leading global commercial services provider EVERSANA as its launch and commercialisation partner to access the UK market. Read the full story.

Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership

Q BioMed Inc. a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, today announced it has engaged EVERSANA™ to immediately support the commercialization of Strontium89, an FDA-approved cancer bone palliation radiotherapy. Read the full story.

MINDPAX and EVERSANA announce U.S. commercialization partnership to launch revolutionary digital therapeutic solution for bipolar disorders

The leadership team at MINDPAX Inc., the leading digital therapeutic company focused on bipolar disorders, today announces its partnership with EVERSANA™ to launch and commercialize its therapeutics in the United States. MINDPAX combines remote clinical assessment and targeted digital therapy to improve patients’ clinical conditions. Read the full story.

Shorla Pharma Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment

Shorla Pharma (‘Shorla’), a specialty pharmaceutical company, and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support the launch and commercialization of Shorla’s oncology portfolio. Read the full story.

GENinCode announces major US commercialisation partnership with EVERSANA

GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, is partnering with EVERSANA to be the launch and commercialisation partner to access the United States market for the GENinCode portfolio of polygenic cardiovascular disease (“CVD”) products focused on genetic risk. Read the full story.

Resverlogix and EVERSANA Announce Partnership to Support the Launch of Apabetalone for COVID-19 in the United States and Canada

Resverlogix Corp. and EVERSANA announced a partnership to support planned commercialization of apabetalone in the United States, Canada (where authorization has been granted to conduct clinical studies of apabetalone for COVID-19) and/or potentially expanding to additional global markets, as Emergency Use Authorization and/or a New Drug Application or equivalent is issued or approved. Read the full story.

Contact Us

Schedule a meeting today!

Contact us to discuss how your asset can immediately benefit from EVERSANA™ COMPLETE Commercialization.

Succeed When Others Fail: Avoiding 20% in Investment Waste During Launch

Posted by EVERSANA Team on March 2, 20223/2/22

It’s a long-standing perception that pharma overspends during launch, but we did not have the data or methodology to understand or validate this notion. Until now. New Research by the Numbers 10: Recent analysis across 10 traditional launches where the manufacturer opted to commercially launch a new drug $345M: The total cost for a manufacturer […]

Case Study: Launching a New Therapy for HER2-Positive Metastatic Breast Cancer

Posted by EVERSANA Team on July 13, 20217/13/21

When MacroGenics partnered with EVERSANA, they had less than five months to launch their first product in the midst of the global pandemic. To meet their timeline and streamlined launch, MacroGenics needed a commercialization partner with an end-to-end platform that would allow them to build their capabilities expeditiously and strategically.

A SpaceX Philosophy to Launching in Pharma

Posted by Maneesh Gupta on June 29, 20216/29/21

In thinking about the economics around the launch of pharmaceutical products, it is useful to compare the situation to another area that has seen its economics evolve in recent years: space travel. For decades, the only reusable space vehicle was NASA’s space shuttle. When the space shuttle was in operation, it could launch a payload […]